Company logo

CYTO - Altamira Therapeutics Ltd.

NASDAQ -> Healthcare -> Biotechnology
Hamilton, Bermuda
Type: Equity

CYTO price evolution
CYTO
(in millions $) 30 Jul 2022 31 Jan 2022 30 Jul 2021 31 Jan 2021
Current assets
Cash $9.29
Short term investments
Net receivables $0.63 $0.94 $0.15 $0.08
Inventory $0.15 $0.84 $0.22
Total current assets $1.93 $3.76 $10.04 $11.62
Long term investments
Property, plant & equipment $0.51 $0.56 $0.03 $0.05
Goodwill & intangible assets
Total noncurrent assets $16.01
Total investments
Total assets $18.48 $18.84 $26.05 $20.8
Current liabilities
Accounts payable $3.16 $3.7 $1.62 $0.76
Deferred revenue
Short long term debt
Total current liabilities $9.79 $4.86 $3.37 $3.03
Long term debt
Total noncurrent liabilities $0.64
Total debt
Total liabilities $10.8 $6.13 $4 $4.03
Shareholders' equity
Retained earnings -$182.6 -$176.02 -$181.02 -$160.64
Other shareholder equity -$0 $0.06 $0.02 $0.06
Total shareholder equity
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Current assets
Cash $0.98 $12.01 $1.39 $5.39
Short term investments
Net receivables $0.94 $0.09 $0.34 $0.32
Inventory $0.84 $0
Total current assets $3.76 $12.39 $2.39 $6.06
Long term investments
Property, plant & equipment $0.56 $0.05 $0.07 $0.03
Goodwill & intangible assets
Total noncurrent assets $9.79 $6.9
Total investments
Total assets $18.84 $22.18 $9.29 $9.88
Current liabilities
Accounts payable $3.54 $0.81 $0.94 $1.81
Deferred revenue
Short long term debt
Total current liabilities $4.86 $3.23 $2.29 $4.56
Long term debt
Total noncurrent liabilities $1.07 $0.92
Total debt
Total liabilities $6.13 $4.3 $3.21 $6.23
Shareholders' equity
Retained earnings -$176.02 -$171.33 -$153.77 -$146.3
Other shareholder equity $0.06 $0.07 -$0.03 -$0.04
Total shareholder equity
(in millions $) 31 Jan 2022 29 Jul 2021 31 Jan 2021 29 Jul 2020
Revenue
Total revenue $0.06
Cost of revenue
Gross Profit -$2.18
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $8.47 $2.86
Operating income
Income from continuing operations
EBIT
Income tax expense $0.03 -$0.01
Interest expense $0.04 -$2.69
Net income
Net income -$10.64 -$5.54
Income (for common shares)
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Revenue
Total revenue $0.06
Cost of revenue
Gross Profit -$2.18
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $13.39 $5.63 $7.31 $10.95
Operating income -$5.63 -$7.31
Income from continuing operations
EBIT
Income tax expense $0.02 -$0.02 -$0.2 $0.16
Interest expense -$0.27 $0.14 $0.03 $0.14
Net income
Net income -$17.39 -$8.75 -$6.67 -$11.5
Income (for common shares)
(in millions $) 31 Jan 2022 30 Jul 2021 31 Jan 2021 29 Jul 2020
Net income -$7.41 -$2.76
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$5.4 -$1.69
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$3.51 -$2.18 -$2.31 -$0.79
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $6.61 $4.22 $16.96 $1.08
Effect of exchange rate $0.29 $0.3 $0.07 $0
Change in cash and equivalents -$10.28 -$3.06 $9.88 -$1.4
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Net income -$8.75 -$6.67
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$5.17 -$8.45
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$3.51 -$2.47 -$3.02 -$1.82
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $6.61 $18.09 $7.43 $5.73
Effect of exchange rate $0.29 $0.08 $0.01 -$0.26
Change in cash and equivalents -$10.28 $10.53 -$4.03 -$9.58
Fundamentals
Market cap $2.49M
Enterprise value N/A
Shares outstanding 853.21K
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 0.20
Quick ratio 0.18